Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE)
Purpose: The CARVE study assesses the effect of Clevidipine, an ultra-short acting vasoselective calcium antagonist, on pulmonary vascular resistance and its utility for pulmonary vasoreactivity testing during right heart catheterization of patients with pulmonary hypertension.
Sponsor: North Texas Veterans Healthcare System
ClinicalTrials.gov Identifier: NCT01121458
Aerobic Exercise in Patients with Pulmonary Hypertension
Purpose: To determine if a rehabilitation exercise program can help people with pulmonary hypertension (PH) increase their physical activity. Patients with PH have an increase in blood pressure in the pulmonary blood vessels (artery, vein, or capillaries) that leads to shortness of breath, dizziness, fainting, and other symptoms.
Sponsor: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00678821
Fat Gain and Cardiovascular Disease Mechanisms
Purpose: This series of novel studies directed at establishing the effects of increased body fat in otherwise healthy individuals will determine the distribution patterns of increased body fat and how both increased body fat and fat distribution relate to changes in blood pressure, and in neural, endothelial, and inflammatory mechanisms which have been implicated in the development and progression of cardiac and vascular disease. We will study non-obese subjects with and without a family history of hypertension.
Sponsor: Mayo Clinic
Collaborator: National Institutes of Health (NIH)
ClinicalTrials.gov Identifier: NCT00589498
Circulating Adenosine Levels Before and After IV Persantine®
Purpose: Persantine is a drug that is routinely used to determine blood flow to the heart in the diagnosis of coronary heart disease. Persantine causes an increase in the adenosine level in the blood. Adenosine is a naturally occurring substance in the body that can increase blood flow. Adenosine is normally removed from the bloodstream by an adenosine transporter, which is a protein that takes up adenosine from the blood into cells. The increase in adenosine levels in the blood is variable, and the cause for this variability is unknown. A mutation for this transporter gene may contribute to this variability, and may alter its function. The purpose of this study is to determine the relationship between the mutation and the transporter function.
Sponsor: University of Connecticut Health Center
Collaborator: US Army Research, DoD
ClinicalTrials.gov Identifier: NCT00760708
back to November articles
INDIANAPOLIS — While many healthcare systems measure the quality of their stroke care, looking at performance early in the vascular disease process can help avoid acute events altogether.
MADISON, WI — Chronic musculoskeletal pain (CMP) affects about one-fourth of the 700,000 veterans deployed during the Persian Gulf War in 1990-1991. A study in the journal Pain pointed out that the cause of their... View Article